Respiratory Syncytial Virus Infections Clinical Trial
Official title:
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Verified date | August 2018 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of a
single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in
RSV-seronegative infants and children 6 to 24 months of age.
This study is a companion study to IMPAACT 2012.
Status | Terminated |
Enrollment | 8 |
Est. completion date | April 30, 2018 |
Est. primary completion date | April 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 24 Months |
Eligibility |
Inclusion Criteria: - Greater than or equal to 6 months (greater than or equal to 180 days) of age at the time of screening and less than 25 months (less than 750 days) of age - Participant is in good health based on review of the medical record, history, and physical examination, without evidence of chronic disease - Parents/guardians are willing and able to provide written informed consent - Seronegative for RSV antibody, defined as a serum RSV-neutralizing antibody titer less than 1:40 at screening from a sample collected no more than 42 days prior to inoculation - Is growing at a normal velocity for age as demonstrated on a standard growth chart AND - If less than 1 year of age: has a current height and weight above the 5th percentile - If 1 year of age or older: has a current height and weight above the 3rd percentile for age - Participant has received routine immunizations appropriate for age (as per Center for Disease Control Advisory Committee on Immunization Practices [ACIP]) - Participant is expected to be available for the duration of the study Exclusion Criteria: - Known or suspected HIV infection or impairment of immunological functions - Receipt of immunosuppressive therapy, including any systemic, including either nasal or inhaled, corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment is not an exclusion. - Bone marrow/solid organ transplant recipient - Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities - Previous receipt of a licensed or investigational RSV vaccine or receipt of placebo in any IMPAACT RSV study or previous receipt of or planned administration of any anti-RSV product (such as ribavirin or RSV Ig or RSV mAb) - Previous anaphylactic reaction - Previous vaccine-associated adverse reaction that was Grade 3 or above - Known hypersensitivity to any study product component - Heart disease. Note: Participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled - Lung disease, including any history of reactive airway disease or medically documented wheezing - Member of a household that contains, or will contain, an infant who is less than 6 months of age at the enrollment date through Day 28 - Member of a household that contains another child who is, or is scheduled to be, enrolled in CIR 311, 312 or 313 AND there has been or will be an overlap in residency during that other child's participation in the study's Acute Phase (Days 0 to 28) - Member of a household that contains an immunocompromised individual, including but not limited to: - a person who is HIV infected - a person who has received chemotherapy within the 12 months prior to enrollment - a person receiving immunosuppressant agents - a person living with a solid organ or bone marrow transplant - Attends a daycare facility and shares a room with infants less than 6 months of age, and parent/guardian is unable or unwilling to suspend daycare for 28 days following inoculation - Any of the following events at the time of enrollment: - fever (temporal or rectal temperature of greater than or equal to 100.4°F), or - upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or - nasal congestion significant enough to interfere with successful inoculation, or - otitis media - Receipt of the following prior to enrollment: - any killed vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or - any live vaccine, other than rotavirus vaccine, within the 28 days prior, or - another investigational vaccine or investigational drug within 28 days prior - Scheduled administration of the following after planned inoculation: - killed vaccine or live-attenuated rotavirus vaccine within the 14 days after, or - any live vaccine other than rotavirus in the 28 days after, or - another investigational vaccine or investigational drug in the 56 days after - Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months - Receipt of any of the following medications within 3 days of study enrollment: - systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or - intranasal medications, or - other prescription medication except as listed below - Receipt of salicylate (aspirin) or salicylate-containing products within the past 28 days - Born at less than 34 weeks gestation - Born at less than 37 weeks gestation and less than 1 year of age at the time of enrollment - Suspected or documented developmental disorder, delay, or other developmental problem - Previous receipt of supplemental oxygen therapy in a home setting |
Country | Name | City | State |
---|---|---|---|
United States | Center for Immunization Research East, Johns Hopkins Bayview Medical Center Campus | Baltimore | Maryland |
United States | Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health | Baltimore | Maryland |
United States | Center for Immunization Research South | Laurel | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grades of study product-related solicited adverse events (AEs) | Measured through Day 28 | ||
Primary | Grades of study product-related unsolicited AEs | Measured through Day 28 | ||
Primary | Grades of study product-related serious adverse events (SAEs) | Measured through Day 56 | ||
Primary | Number of participants with infection with vaccine virus | Defined as 1) vaccine virus identified in a nasal wash from Study Day 0-28 (a binary outcome based on nasal washes done throughout the study period; Day 0 nasal wash will be counted as baseline) or 2) greater than or equal to 4-fold rise in RSV neutralizing antibody titer from Study Day 0-56 | Measured through Day 56 | |
Primary | Peak titer of vaccine virus shed | Measured through Day 28 | ||
Primary | Duration of vaccine virus shedding in nasal washes measured by culture | Measured through Day 28 | ||
Primary | Duration of vaccine virus shedding in nasal washes measured by RT-PCR | Measured through Day 28 | ||
Primary | Frequency of a greater than or equal to 4-fold rise in RSV-neutralizing antibody titer | Measured through Day 56 | ||
Primary | Antibody responses to RSV F glycoprotein as assessed by enzyme-linked immunosorbent assay (ELISA) | Measured through Day 56 | ||
Secondary | Frequency of symptomatic, medically attended respiratory and febrile illness in the vaccine and placebo recipients who experience natural infection with wild-type RSV during the subsequent RSV season | Will be measured through the subsequent RSV season (November 1 in the calendar year of study entry to March 31 in the calendar year following study entry) | Measured through participant's last study visit, up to a total of 6 to 12 months after study entry depending on when participants enroll in the study | |
Secondary | Measurement of antibody responses in the vaccine and placebo recipients who experience natural infection with wt RSV during the subsequent RSV season | Will be measured at the post-RSV season visit (between April 1 and April 30 in the calendar year following study entry) | Measured at participant's last study visit, up to a total of 6 to 13 months after study entry depending on when participants enroll in the study | |
Secondary | Frequency of B cell responses to vaccine | Will be measured at the post-RSV season visit (between April 1 and April 30 in the calendar year following study entry) | Measured through participant's last study visit, up to a total of 6 to 13 months after study entry depending on when participants enroll in the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT05590403 -
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
|
Phase 3 |